Skip to content

Clinical Study of Patients with Airway Hyperresponsiveness companied by Cough Variant Asthma

Clinical Study of Patients with Airway Hyperresponsiveness companied by Cough Variant Asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010689
Enrollment
Unknown
Registered
2017-02-20
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CVA

Interventions

study group:Allergy Decoction & Montelukast

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. From 18 to 70 years old; 2. The symptom of cough lasts more than 8 weeks; 3. Coughing with little spit or smell and cold air can trigger cough; 4. Sternum without obvious abnormality; 5. FeNO>25ppb; 6. Excluding the disgnoise of acute cough, reflux esophagitis and upper airway cough syndrome; 7. Free from other respiratory diseases; 8. Agree and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who can't meet the standard mentioned above; 2. Be allergic to investigational medicinal products; 3. Renal function impairment or liver function higher than normal 1.5 tiomes; 4. Alcoholism or history of drug dependence; 5. Pregnance and breastfeeding women; 6. Patients have poor compliance or difficulty in communication; 7. Patients who participate in other clinical trials in the last month.

Design outcomes

Primary

MeasureTime frame
Daytime cough symptom score;night cough symptom score;FeNO;

Countries

China

Contacts

Public ContactYong Zhu

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

13701170254@139.com+86 13701170254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026